Galiximab in relapsed hodgkin lymphoma

Clinical Advances in Hematology and Oncology

Volumn 8, Issue 10, 2010, Pages 669-670

  Smith, Sonali M ^a  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; BORTEZOMIB; BRENTUXIMAB VEDOTIN; GALIXIMAB; MONOCLONAL ANTIBODY; SGN 35; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; HODGKIN DISEASE; HUMAN; IMMUNE SYSTEM; INFECTION; LIVER FUNCTION TEST; MONOTHERAPY; REED STERNBERG CELL; SIDE EFFECT; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE II AS TOPIC; HODGKIN DISEASE; HUMANS; NEOPLASM RECURRENCE, LOCAL;

EID: 78649967675     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (2)

1. Smith SM, Bartlett N, Johnson JL, et al. Galiximab, an anti-CD80 primatized monoclonal antibody, in relapsed Hodgkin lymphoma: final results of CALGB 50602. J Clin Oncol (ASCO Meeting Abstracts). 2010; 28(15s). Abstract 8039.
2. Blum KA, Johnson JL, Niedzwiecki D, et al. A phase II study of bortezomib in relapsed Hodgkin lymphoma: preliminary results of CALGB 50206. J Clin Oncol (ASCO Meeting Abstracts). 2006; 24(18s). Abstract 7576.